药械指南

订阅

MedSci主页 / 所有栏目 / 药械指南

FDA联合口服避孕药的临床药物相互作用研究（草案） 2020

2020-11-19 美国食品和药品监督管理局 FDA

避孕药

FDA联合口服避孕药的临床药物相互作用研究（草案） 2020

中文标题：

FDA联合口服避孕药的临床药物相互作用研究（草案） 2020

发布机构：

美国食品和药品监督管理局

发布日期：

2020-11-19

简要介绍：

FDA联合口服避孕药的临床药物相互作用研究（草案） 2020

相关资料下载：
[AttachmentFileName(sort=1, fileName=66.pdf)] GetToolGuiderByIdResponse(projectId=1, id=c14861c002066164, title=FDA联合口服避孕药的临床药物相互作用研究（草案） 2020, enTitle=, guiderFrom=FDA, authorId=0, author=, summary=FDA联合口服避孕药的临床药物相互作用研究（草案） 2020, cover=, journalId=0, articlesId=null, associationId=486, associationName=美国食品和药品监督管理局, associationIntro=美国食品和药品监督管理局是美国公共卫生及服务部的一个代理商，其由委员会办公室和4个监督核心功能理事机构组成。, copyright=0, guiderPublishedTime=Thu Nov 19 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<p>FDA联合口服避孕药的临床药物相互作用研究（草案） 2020</p>, tagList=[TagDto(tagId=4333, tagName=避孕药)], categoryList=[CategoryDto(categoryId=11, categoryName=药械, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=1, opened=0, paymentType=, paymentAmount=40, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3176, appHits=55, showAppHits=0, pcHits=373, showPcHits=3121, likes=0, shares=7, comments=3, approvalStatus=1, publishedTime=Sat Mar 06 16:35:40 CST 2021, publishedTimeString=2020-11-19, pcVisible=1, appVisible=1, editorId=4754896, editor=fbzhang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=fbzhang, createdTime=Sat Mar 06 16:35:34 CST 2021, updatedBy=4754896, updatedName=fbzhang, updatedTime=Sat Jan 06 09:08:45 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=66.pdf)])
66.pdf
下载请点击：
评论区 (2)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1079364, encodeId=affb10e93641c, content=写得好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201203/23c7fab364194717836769d96a50cdde/783e78a2b4a4410c9dae7e959ba1c77c.jpg, createdBy=1efd2552192, createdName=福尔摩妮, createdTime=Mon Dec 13 00:14:01 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977023, encodeId=c1b99e7023a5, content=嘿嘿嘿, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5aec5112847, createdName=1461bde6m98暂无昵称, createdTime=Sat Jun 26 10:34:34 CST 2021, time=2021-06-26, status=1, ipAttribution=)]
    2021-12-13 福尔摩妮

    写得好

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1079364, encodeId=affb10e93641c, content=写得好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201203/23c7fab364194717836769d96a50cdde/783e78a2b4a4410c9dae7e959ba1c77c.jpg, createdBy=1efd2552192, createdName=福尔摩妮, createdTime=Mon Dec 13 00:14:01 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977023, encodeId=c1b99e7023a5, content=嘿嘿嘿, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5aec5112847, createdName=1461bde6m98暂无昵称, createdTime=Sat Jun 26 10:34:34 CST 2021, time=2021-06-26, status=1, ipAttribution=)]
    2021-06-26 1461bde6m98暂无昵称

    嘿嘿嘿

    0